Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01990352 · ClinicalTrials.gov registry record · Phase 2
Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
A Phase 2 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01990352 is a Phase 2 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 24 participants.
The verdict
NCT01990352, a Phase 2 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate if low BRCA1 protein expression has a preferential effect on response when metastatic breast cancer patients are treated with DNA damaging chemotherapy agent, compared to historical controls Secondary Objective: To evaluate if low BRCA1 protein expression has a preferential effect on tumor progression when metastatic breast cancer patients are treated with DNA damaging chemotherapy agent, compared to historical controls
Interventions
- DRUG Pegylated liposomal doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-11-05 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01990352
The ClinicalTrials.gov registry entry for NCT01990352 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegylated liposomal doxorubicin is the first listed.
NCT01990352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01990352 about?
NCT01990352 is a clinical study titled "Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy". Primary Objective: To evaluate if low BRCA1 protein expression has a preferential effect on response when metastatic breast cancer patients are treated with DNA damaging chemotherapy agent, compared to historical controls Secondary Objective: To evaluate if low BRCA1 protein expression has a prefer...
What is the current status of trial NCT01990352?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2013-11-05. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT01990352?
The interventions under investigation include: Pegylated liposomal doxorubicin (DRUG).
Who is sponsoring clinical trial NCT01990352?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.